2025年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG1529 | Tokito T, Yamada K, Ishii H, et al.
: Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529). Radiation Oncology 20:2, 2025. https://doi.org/10.1186/s13014-024-02577-5 |
| TORG1834 | Miura S, Tanaka H, Misumi T, et al.
: Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 .Journal of Clinical Oncology 43 (18) : 2049-2058, 2025. https://ascopubs.org/doi/10.1200/JCO-24-02007 |
| TORG2040 | Fukui T, Mamesaya N, Takahashi T, et al.
: A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040). Journal of Thoracic Oncology 20 (5): 665-675, 2025. https://doi.org/10.1016/j.jtho.2024.12.027 |
2024年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG1424 | Nogami N, Kubo T, Bessho A, et al.: A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL) .Japanese Journal of Clinical Oncology. 54 (7): 805-812, 2024. https://doi.org/10.1093/jjco/hyae044 |
| TORG1835 | Ikeda S, Ogura T, Kato T, et al.
Nintedanib plus chemotherapy for small cell lung cancer with comorbid Idiopathic pulmonary fibrosis. Annals of the American Thoracic Society 21 (4) : 635-643, 2024. https://doi.org/10.1513/AnnalsATS.202311-941OC |
| TORG1937 | Nakamichi S, Kubota K, Misumi T, et al.: Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study). Clinical Cancer Research 30 (6) : 1104-1110, 2024. https://doi.org/10.1158/1078-0432.CCR-23-2568 |
| TG2101 Osi-risk |
Nishioka N, Endo M, Notsu A, et al.: Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101) . Targeted Oncology 19: 423-433, 2024. https://doi.org/10.1007/s11523-024-01048-x |
2023年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0503 （QOL） |
Matsuda A, Yamaoka K, Kunitoh H, et al.: Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503. Quality of Life Research 32: 2629-2637, 2023 https://doi.org/10.1007/s11136-023-03424-y |
| TORG1321 | Kasai T, Mori K, Nakamura Y, et al.: Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321. Cancer Medicine 12 (14): 14988-14999, 2023 https://doi.org/10.1002/cam4.6135 |
| TORG1426 | Ichikawa Y, Seki N, Honda T, et al.: Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426. Translational Cancer Research 12 (4): 873-886, 2023 https://dx.doi.org/10.21037/tcr-22-2144 |
| JCOG1201/ TORG1528 |
Shimokawa T, Okamoto H, Machida R,et al.: Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung Cancer 181:107195, 2023 https://doi.org/10.1016/j.lungcan.2023.107195 |
| TORG1938 | Okuma Y, Nomura S, Ninomiya K, et al.: Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study). Future Oncol 19: 1515-1521, 2023 https://doi.org/10.2217/fon-2022-1128 |
| TORG2241 | Nakamichi S, Kubota K, Matsuyama K, et al.: A Phase II Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clin Lung Cancer 25 (1): 85-90, 2024 https://doi.org/10.1016/j.cllc.2023.09.006 |
2022年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG1018 related article |
Taniguchi Y, Okamoto H, Shimokawa T, et al.: Concurrent chemoradiotherapy with cisplatin+S-1 versus cisplatin+other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data. BMC Pulmonary Medicine 22: 31-42, 2022 |
| TORG1630 | Taniguchi Y, Shimokawa T, Takiguchi Y et al.: A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small-cell lung cancer: TORG1630. Clinical Cancer Research 22: 4402-4409, 2022 doi.org/10.1158/1078-0432.ccr-22-1687 |
| TORG1936 | Ikeda S, Kato T, Kenmotsu H, et al.: Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. The Oncologist 27: 720-e702, 2022 doi: 10.1093/oncolo/oyac118 |
| TORG1936 related article |
Ikeda S, Misumi T, Kato T, et al.: Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases Really Mild and Easily Manageable? CHEST 162: E65-E66, 2022. doi: 10.1016/j.chest.2022.02.057 |
| TORG2040 | Fukui T, Sasaki J, Igawa S, et al.: Rationale and protocol design of a phase II study of frst-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC Cancer 22: 1314, 2022 https://doi.org/10.1186/s12885-022-10409-6 |
2021年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG1018 | Shimokawa T, Yamada K, Tanaka H, et al.: Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. Cancer Medicine 10: 626-633, 2021 |
| TORG1632 | Noro R, Igawa S, Bessho A, et al.: A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung Cancer 161: 49-54, 2021 |
| TORG1936 related article |
Ikeda S, Kato T, Kenmotsu H, et al.Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer 151: 249-251, 2021 (Letter to the Editor) doi.org/10.1016/j.ejca.2021.03.050 |
2020年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0503 | Kubota K, Kunitoh H, Seto T, et al.: Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503. Lung Cancer 141: 32-36, 2020 |
| TORG0808 TORG0913 |
Nakahara Y, Shimokawa T, Misumi Y, et al.: Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913. Investigational New Drugs (published online 15 Aug 2020) doi: 10.1007/s10637-020-00985-4 |
| TORG1320 | Otani S, Sasaki J, Nakahara Y, et al.: Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Investigational New Drugs (published online 07 Nov 2020) doi: 10.1007/s10637-020-01031-z |
| TORG1322 | Zenke Y, Niho S, Umemura S, et al.: Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322. Lung Cancer 146 (8): 182-188, 2020. doi:10.1016/j.lungcan.2020.05.005 |
| TORG1323 | Kozuki T, Nogami N, Hataji O, et al.: Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research 9 (3) : 459-470, 2020. doi: 10.21037/tlcr.2020.03.29 |
| TORG1425 | Miyamoto S, Azuma K, Ishii H, et al.: Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: A multicenter Phase 2 trial. JAMA Oncology 6 (7): e201250. doi: 10.1001/jamaoncol.2020.1250 |
| TORG1834 | Miura S, Yamanaka T, Kato T, et al.: Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer 21 (6): e592-e596. doi: 10.1016/j.cllc.2020.05.011 |
| TORG1835 | Ikeda S, Ogura T, Kato T, et al.: Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920923431 |
| TORG1936 | Ikeda S, Kato T, Kenmotsu H, et al. A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias. Journal of Thoracic Oncology 15: 1935-1942, 2020. doi: 10.1016/j.jtho.2020.08.018 |
| Ikeda S, Kato T, Kenmotsu H, et al.: A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920922022 |
2019年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG1017 | Nakahara Y, Hosomi Y, Shibuya M, et al.: Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Molecular and Clinical Oncology 11: 349-353, 2019 |
2018年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0809 | Niho S, Ikeda N, Michimae H, et al.Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. American Journal of Clinical Oncology 41: 1113-1117, 2018. doi: 10.1097/COC.0000000000000438 |
| TORG1016 | Ikeda S, Kato T, Ogura T, et al.: Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. BMC Cancer 18: 241, 2018 |
2017年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0604 | Misumi Y, Okamoto H, Sasaki J, et al.: Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer 17: 377, 2017 |
2016年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0912 | Takayama K, Atagi S, Imamura F, et al.: Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients?Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer 24 (8): 3473-3480, 2016 |
| TORG1015 | Kozuki T, Nogami N, Kitajima H, et al.: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non- small cell lung cancer in elderly patients: TORG1015. BMC Cancer 16: 306, 2016 |
2015年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0910 | Yamada K, Saito H, Kondo T, et al.: Multicenter phase II study of nedaplatin and irinotecan for patients with squamous cell carcinoma of the lung: Thoracic Oncology Research Group 0910. Anticancer Research 35 (12): 6705-6711, 2015 |
| TORG0911 | Yamada K, Aono H, Hosomi Y, et al.: A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer with EGFR mutations: Thoracic Oncology Research Group 0911. European Journal of Cancer 51 (14) : 1904-1910, 2015 |
| TORG1014 | Takagi Y, Hosomi Y, Oshita F, et al.: Feasibility study of docetaxel plus bevacizumab therapy for elderly patients with non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer 15: 740, 2015 |
2014年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG1016 | Ikeda S, Sekine A, Kato T, et al.: Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case. Japanese Journal of Clinical Oncology 44 (5) : 497-500, 2014 |
2013年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0809 | Niho S, Ikeda N, Michimae H, et al.: Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809. British Journal of Cancer 109 (3) : 545-551, 2013 |
2011年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0705 | Takiguchi Y, Seto T, Ichinose Y, et al.: Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer A Phase II Study. Journal of Thoracic Oncology 6 (1) : 156-160, 2011 |
2010年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0502 | Seto T, Yamanaka T, Wasada I, et al.: Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502. Lung Cancer 69 (2) : 213-217, 2010 |
2006年
| 研究No. | 執筆者/論文タイトル/掲載誌 |
|---|---|
| TORG0301 | Onoda S, Masuda N, Seto T, et al.: Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301. Journal of Clinical Oncology 24 (34) : 5448-5453, 2006 |
